These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27776587)

  • 21. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in Drug Resistance in Childhood Tuberculosis in Cape Town, South Africa.
    Schaaf HS; Garcia-Prats AJ; Draper HR; Rautenbach C; Bosch C; Demers AM; Hesseling AC; Walters E
    Pediatr Infect Dis J; 2020 Jul; 39(7):604-608. PubMed ID: 32520889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojjam zone, northwest Ethiopia.
    Adane K; Ameni G; Bekele S; Abebe M; Aseffa A
    BMC Public Health; 2015 Jun; 15():572. PubMed ID: 26092570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
    Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N
    PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
    Ishiwada N; Tokunaga O; Nagasawa K; Ichimoto K; Kinoshita K; Hishiki H; Kohno Y
    Tohoku J Exp Med; 2013 Mar; 229(3):221-5. PubMed ID: 23470647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlates of treatment outcomes and drug resistance among pulmonary tuberculosis patients attending tertiary care hospitals of Kolkata, India.
    Goswami A; Chakraborty U; Mahapatra T; Mahapatra S; Mukherjee T; Das S; Das A; Dey SK; Ray S; Bhattacharya B; Pal NK
    PLoS One; 2014; 9(10):e109563. PubMed ID: 25289974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia.
    Mekonnen F; Tessema B; Moges F; Gelaw A; Eshetie S; Kumera G
    BMC Infect Dis; 2015 Oct; 15():461. PubMed ID: 26503269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes.
    Vidyaraj CK; Chitra A; Smita S; Muthuraj M; Govindarajan S; Usharani B; Anbazhagi S
    J Epidemiol Glob Health; 2017 Dec; 7(4):289-294. PubMed ID: 29110871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid-Resistant Rifampicin-Susceptible Tuberculosis in Children.
    Morales Pérez C; Gomez-Pastrana D; Aragón Fernández C; Pérez Escolano E
    Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):388-390. PubMed ID: 30635203
    [No Abstract]   [Full Text] [Related]  

  • 34. [Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case].
    Hançerli Törün S; Acar EM; Somer A; Erköse G; Şatana D; Bayramoğlu Z; Çalışkan E; Kılıçaslan Z
    Mikrobiyol Bul; 2018 Jan; 52(1):89-95. PubMed ID: 29642833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa.
    Cox HS; McDermid C; Azevedo V; Muller O; Coetzee D; Simpson J; Barnard M; Coetzee G; van Cutsem G; Goemaere E
    PLoS One; 2010 Nov; 5(11):e13901. PubMed ID: 21085569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.
    Dramowski A; Morsheimer MM; Jordaan AM; Victor TC; Donald PR; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):76-81. PubMed ID: 22236850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.